2023
Improving HIV and HCV Testing in Substance Use Disorder Programs (SUDs) That Provide Medications for Opiate Use Disorder (MOUD): Role of Addressing Barriers and Implementing Universal and Site-Specific Approaches
Brooks R, Wegener M, Freeman B, Fowles C, Madden L, Tetrault J, Nichols L, Altice F, Villanueva M. Improving HIV and HCV Testing in Substance Use Disorder Programs (SUDs) That Provide Medications for Opiate Use Disorder (MOUD): Role of Addressing Barriers and Implementing Universal and Site-Specific Approaches. Health Promotion Practice 2023, 24: 1018-1028. PMID: 37439759, DOI: 10.1177/15248399231169791.Peer-Reviewed Original ResearchMeSH KeywordsCoinfectionHepacivirusHepatitis CHIV InfectionsHumansOpiate AlkaloidsSubstance-Related DisordersConceptsHIV/HCV coinfectionSubstance use disorder programsHCV testingOpiate use disorderHCV coinfectionUse disordersNominal group techniqueSubstance use disorder treatment centersCascade of careRates of HIVDisorder treatment centersQuality improvement effortsRate of testingHCV acquisitionHCV cureImproving HIVSUD clinicsHepatitis CHIV testingPrior diagnosisSubsequent referralReferral ratesHIV epidemicHIVTreatment centersChallenges to Achieving HCV Micro-Elimination in People With HIV in the United States: Provider Perspectives and the Role of Implicit Bias
DiDomizio E, Chandra D, Nichols L, Villanueva M, Altice F. Challenges to Achieving HCV Micro-Elimination in People With HIV in the United States: Provider Perspectives and the Role of Implicit Bias. Health Promotion Practice 2023, 24: 998-1008. PMID: 37440258, DOI: 10.1177/15248399231169928.Peer-Reviewed Original ResearchMeSH KeywordsBias, ImplicitDrug UsersHepacivirusHepatitis CHIV InfectionsHumansSubstance Abuse, IntravenousUnited StatesConceptsNominal group techniqueHealth care decisionsProvider perspectivesEligibility criteriaHIV/HCVEffective antiviral medicationsPatient eligibility criteriaFacilitators of treatmentMicro-EliminationHCV treatmentAntiviral medicationsOpioid epidemicProvider knowledgePatient involvementPatient engagementDifferent clinicsRelated stigmaHCVCare decisionsHIVPatientsTreatmentGroup sessionsMost barriersFocus group sessionsFuture Directions for HIV/HCV Care: Lessons Learned From Local Evaluation Projects in Texas and Connecticut and Implications for Practice and Health Promotion
Villanueva M. Future Directions for HIV/HCV Care: Lessons Learned From Local Evaluation Projects in Texas and Connecticut and Implications for Practice and Health Promotion. Health Promotion Practice 2023, 24: 1050-1054. PMID: 37439561, DOI: 10.1177/15248399231169919.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsConnecticutHealth PromotionHepacivirusHepatitis CHIV InfectionsHumansTexasConceptsServices Administration's Special ProjectsHCV elimination goalsSystem-level barriersHCV careHCV cureHepatitis CElimination goalsHealth promotionYale University SchoolIndividualized approachPriority populationsLocal implementation strategiesLevel barriersUniversity SchoolImplementation strategiesHCVHIVPatientsSan AntonioEvaluation projectCareCreating a Longitudinal HCV Care Cascade for Persons With HIV/HCV Coinfection in Selected HIV Clinics Using Data to Care Methods
Brooks R, Wegener M, Speers S, Nichols L, Sideleau R, Valeriano T, Buchelli M, Villanueva M. Creating a Longitudinal HCV Care Cascade for Persons With HIV/HCV Coinfection in Selected HIV Clinics Using Data to Care Methods. Health Promotion Practice 2023, 24: 1039-1049. PMID: 37439600, DOI: 10.1177/15248399231169792.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsCoinfectionFemaleHepacivirusHepatitis CHepatitis C, ChronicHIV InfectionsHumansMaleConceptsHIV/HCV coinfectionHCV coinfectionHepatitis C virusSVR ratesHCV treatmentHIV clinicTreatment cascadeTreatment statusSustained virologic response ratesHCV care cascadeHCV treatment cascadeHCV treatment statusVirologic response ratesHIV viral suppressionPatient treatment statusPublic health approachCare cascadeHepatitis CViral suppressionActing antiviralsTreatment initiationC virusResponse rateClinical staffCoinfectionCharacterizing Persons With HIV/HCV Coinfection Who Remain Untreated for Hepatitis C at Four HIV Clinics in Connecticut (CT): Role of Multiple Overlapping Barriers at the Individual and Clinic System Levels
Zhao A, Wegener M, Brooks R, Mininberg L, Helou E, Maughan A, Villanueva M. Characterizing Persons With HIV/HCV Coinfection Who Remain Untreated for Hepatitis C at Four HIV Clinics in Connecticut (CT): Role of Multiple Overlapping Barriers at the Individual and Clinic System Levels. Health Promotion Practice 2023, 24: 1029-1038. PMID: 37439687, DOI: 10.1177/15248399231169793.Peer-Reviewed Original ResearchConceptsHIV/HCV coinfectionHepatitis C virusHCV coinfectionHIV clinicDirect-acting antiviral medicationsHIV transmission risk factorsPrimary care HIV clinicClinic-level barriersHCV elimination targetsChronic HCV infectionRetrospective chart reviewPatient-level barriersClinical practice patternsMedication-assisted treatmentTransmission risk factorsIllicit substance usePatient-specific issuesLack of transportationSubstance use problemsMental health issuesHCV cureHCV infectionHCV treatmentHepatitis CUntreated patientsExpanded or Risk Factor-Based Annual Screening for Hepatitis C Virus (HCV) Among Persons With HIV: Which Is the Best Approach?
Hao R, Brooks R, Zelenev A, Spinner G, Barakat L, Villanueva M. Expanded or Risk Factor-Based Annual Screening for Hepatitis C Virus (HCV) Among Persons With HIV: Which Is the Best Approach? Health Promotion Practice 2023, 24: 1009-1017. PMID: 37439817, DOI: 10.1177/15248399231169794.Peer-Reviewed Original ResearchConceptsHepatitis C virusRisk factor-based screeningElectronic medical recordsHIV clinicAnnual screeningC virusRisk factorsScreening siteAnnual screening ratesNew HCV diagnosesClinical decision support toolRisk factor assessmentPublic health expertsHCV testingHCV casesClinical decision supportHCV diagnosisHCV testScreening ratesProspective studyMedical recordsPositivity ratePositive casesUnprotected sexClinic
2022
Perceptions Towards HCV Treatment with Direct Acting Antivirals (DAAs): A Qualitative Analysis with Persons with HIV/HCV Co-infection Who Delay or Refuse Treatment
Brothers S, DiDomizio E, Nichols L, Brooks R, Villanueva M. Perceptions Towards HCV Treatment with Direct Acting Antivirals (DAAs): A Qualitative Analysis with Persons with HIV/HCV Co-infection Who Delay or Refuse Treatment. AIDS And Behavior 2022, 27: 119-133. PMID: 35776253, PMCID: PMC9663279, DOI: 10.1007/s10461-022-03749-8.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsCoinfectionHepacivirusHepatitis CHepatitis C, ChronicHIV InfectionsHumansUnited StatesConceptsDirect acting antiviralsHIV/HCVDAA treatmentHCV treatmentHIV/HCV Co-infectionDAA treatment uptakeHCV Co-InfectionPatient-level barriersHCV diseaseAdherence supportHepatitis CActing antiviralsTreatment uptakeCo-InfectionTreatment barriersHCVTreatmentPWHAntiviralsQualitative interviewsHIVDiseaseDiagnosisPersonsUptake
2021
Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients
Sivakumar A, Madden L, DiDomizio E, Eller A, Villanueva M, Altice FL. Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients. International Journal Of Drug Policy 2021, 101: 103570. PMID: 34954493, PMCID: PMC8685180, DOI: 10.1016/j.drugpo.2021.103570.Peer-Reviewed Original ResearchConceptsOpioid use disorderHepatitis C virusSyringe services programDifferentiated care modelPerson visitsC virusCare modelUse disordersInitiation of DAAChronic HCV infectionEvidence-based treatmentsCOVID-19Initial phlebotomyVirological responseHCV infectionHCV treatmentAdditional patientsElevated riskPatientsClient-centred approachPWIDHIVPerson contactTreatment demandLaboratory screening